AbbVie has announced positive topline results from its Phase 3 LUNA study evaluating atogepant for the preventive treatment of menstrual migraine in adults. Atogepant, sold as Qulipta in the US and Aquipta
MorePaysign’s Vice President of Patient Affordability, Logan Melchione, says clients are consistently frustrated by the dual burden of diversion and fraud on their programmes. Both problems drain copay assistance programmes of critical
MoreHDA’s Kala Shankle is urging wholesale distributors and third-party logistics providers not to wait for Washington before preparing for national licensure requirements. Shankle’s core message is that the work required ahead of
MoreDHL Group is significantly expanding its Life Sciences and Healthcare capabilities in Singapore through a series of major infrastructure investments targeting the Asia Pacific market. The expansion builds on the earlier opening
MoreCaris Life Sciences (NASDAQ: CAI) has launched a national advertising campaign called “Math,” starring award-winning actor, producer and director Kevin Costner. The campaign is designed to raise public awareness about the importance
MoreThe shift toward home-administered pharmaceutical therapies is accelerating, prompting organisations to fundamentally rethink how they guide patients through complex clinical transitions. Healthcare companies are under growing pressure to ensure patients feel equipped
MoreBayer HealthCare Pharmaceuticals has secured expanded FDA accelerated approval for sevabertinib, sold as Hyrnuo, targeting previously untreated HER2-mutated non-small cell lung cancer patients. The U.S. Food and Drug Administration granted the expanded
MoreThe pharmaceutical industry’s shift to 12-digit National Drug Codes carries its greatest risk not inside individual systems, but at the handoffs between organisations. That is the central warning from Liberty Dewey, manager
MorePharmaceutical giant Merck & Co. (MRK) has filed notice with New Jersey state officials confirming 54 additional layoffs at its Rahway location. The filing was made in September with the New Jersey
MorePresident Donald Trump announced nine new most-favoured-nation agreements with pharmaceutical manufacturers on 31 August, expanding the programme significantly. The latest additions bring the total number of participating companies to 26, which the
More
